This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
EMA Panel Endorses Novavax's (NVAX) COVID Jab for Full Approval
by Zacks Equity Research
Novavax's (NVAX) protein-based COVID-19 vaccine gets recommendation for full marketing authorization in COVID-19 patients from European Medicines Agency.
Novo Nordisk (NVO) Growth Hormone Drug Gets Positive CHMP Opinion
by Zacks Equity Research
Novo Nordisk (NVO) gets CHMP recommendation approval for Sogroya for expanded use in children and adolescents with growth hormone deficiency.
Pfizer's (PFE) COVID-19 Oral Treatment Gets FDA Nod in Adults
by Zacks Equity Research
Per the FDA, Pfizer's (PFE) Paxlovid is the first oral antiviral pill approved in the United States to treat COVID-19 in adults. The drug was granted emergency use authorization by the FDA in 2021.
Allison Transmission and Alico have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Allison Transmission and Alico have been highlighted as Zacks Bull and Bear of the Day.
Novo Nordisk (NVO) Collaborates for Gene-Editing Therapies
by Zacks Equity Research
Novo Nordisk (NVO) partners with Life Edit Therapeutics to discover and develop gene-editing therapies for rare and cardiometabolic diseases.
US Debt-Ceiling Crisis Looms: How Will It Impact Medical Stocks?
by Indrajit Bandyopadhyay
The United States is on the brink of a debt-ceiling crisis that could have devastating consequences for the global economy. Will the looming fiscal showdown shake the world?
Novo Nordisk (NVO) Announces Positive Obesity Program Data
by Zacks Equity Research
Novo Nordisk's (NVO) late-stage study of once-daily oral semaglutide 25 mg and 50 mg in obesity shows superior weight loss at week 68 compared with placebo.
Pfizer's (PFE) Oral Diabetes Drug Aids in Weight Loss, Stock Up
by Zacks Equity Research
Data from a phase II study published in JAMA showed that Pfizer's (PFE) danuglipron reduces glycated hemoglobin and fasting plasma glucose (at all doses) and body weight (at the highest doses) at week 16.
Company News for May 23, 2023
by Zacks Equity Research
Companies in The News Are: GOOGL, PFE, NVO, CBRE, PG
Pfizer's (PFE) RSV Vaccine for Infants Gets FDA Panel Vote
by Zacks Equity Research
The FDA's decision on Pfizer's (PFE) BLA seeking approval for its RSV vaccine candidate in infants through maternal immunization is expected in August.
Pharma Stock Roundup: FDA Nod to ABBV's Rinvoq for New Indication & Other Updates
by Kinjel Shah
FDA panel votes in favor of Pfizer's (PFE) experimental maternal RSV vaccine. FDA approves AbbVie's (ABBV) Rinvoq for Crohn's Disease.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Pfizer (PFE) to Raise $31B in Debt to Fund Seagen (SGEN) Deal
by Zacks Equity Research
Pfizer (PFE) offers bonds worth $31 billion to fund its pending acquisition of cancer drugmaker, Seagen (SGEN).
FTC May Reportedly Block Amgen's (AMGN) $28B Horizon Buyout
by Zacks Equity Research
Unconfirmed reports suggest that the FTC may challenge the $28-billion buyout of Horizon Therapeutics (HZNP) by Amgen.
The Zacks Analyst Blog Highlights Visa, Pfizer, SAP SE, International Business Machines and The Boeing
by Zacks Equity Research
Visa, Pfizer, SAP SE, International Business Machines and The Boeing are part of the Zacks top Analyst Blog.
Top Analyst Reports for Visa, Pfizer & SAP
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), Pfizer Inc. (PFE) and SAP SE (SAP).
Insiders Are Diving Into These 3 Stocks
by Derek Lewis
When an insider buys, it can deliver a positive message to shareholders, indicating that they're confident in the long-term picture of the business.
Biotech ETFs Pop on M&A Resurgence
by Neena Mishra
2023 could be a year of heightened biotech dealmaking activity
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Deciphera (DCPH) Q1 Earnings Match Estimates, Sales Miss
by Zacks Equity Research
Deciphera Pharmaceuticals (DCPH) reports mixed first-quarter 2023 results as its earnings are in line with the Zacks Consensus Estimate, while revenues miss the same.
Pfizer (PFE) Q1 Earnings Beat, COVID Jab Sales Down as Expected
by Zacks Equity Research
Pfizer (PFE) beats estimates for Q1 earnings and sales. Revenues from its COVID-19 vaccine, Comirnaty declined, as expected.
Market Eagerly Awaits Outcome of Fed FOMC Meet
by Zacks Equity Research
Market Eagerly Awaits Outcome of Fed FOMC Meet.
JOLTS Data After the Bell, Q1 Reports for PFE, UBER & More
by Mark Vickery
The JOLTS report for March will be out today, making it the first of several employment-related releases out this week.
Pfizer (PFE) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Pfizer (PFE) delivered earnings and revenue surprises of 23% and 7.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Novo Nordisk (NVO) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Novo Nordisk's (NVO) Diabetes and Obesity Care products are expected to have increased sales in the first quarter of 2023, amid severe competition and pricing pressure in the United States.